Figure 6.

Low-dose cisplatin fails to promote anti-TIGIT mAb treatment against CT26 colon cancer. (A), Experimental scheme for CT26 colon cancer model used in (B, C): mice were given injection of Rat IgG, anti-TIGIT (10 mg/kg), OX (1.5 mg/kg), anti-TIGIT combined with OX, cisplatin (CIS, 0.25 mg/kg) or anti-TIGIT combined with CIS intraperitoneally (i.p.) after injection of 5×10⁴ CT26 tumor cells subcutaneously (s.c.) on day 0. (B), Tumor size measurement at each time point. (n=15-17 mice per group). (C), Overall survival of CT26-bearing mice with various treatments. (n=7 or 8 mice per group). Data were representative of at least two independent experiments. Error bars represent means ± SEM. Statistical significance was determined using two-way ANNOVA (B) or Mantel–Cox test (C). ns, p > 0.05; *p < 0.05; **p < 0.01 and ***p < 0.001.